Cargando…
MALT1 reflects inflammatory cytokines, disease activity, and its chronological change could estimate treatment response to infliximab in Crohn's disease patients
BACKGROUND: Mucosa‐associated lymphoid tissue lymphoma translocation protein 1 (MALT1) mediates the immunity and inflammatory response in multiple ways to be intimately involved in the progression of autoimmune diseases. This study intended to explore the linkage of MALT1 with inflammation, disease...
Autores principales: | Dong, Xiaoxia, Chen, Xiaoxiao, Ren, Yuxiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550982/ https://www.ncbi.nlm.nih.gov/pubmed/36036788 http://dx.doi.org/10.1002/jcla.24650 |
Ejemplares similares
-
Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007) -
Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022) -
Infliximab Therapy Could Decrease the Risk of the Development of Thyroid Disorders in Pediatric Patients With Crohn's Disease
por: Furtak, Aleksandra, et al.
Publicado: (2020) -
Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011) -
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)